AMENDMENT TO THE AMENDMENT IN THE NATURE OF A SUBSTITUTE TO COMMITTEE PRINT FOR SUBTITLE E RELATING TO DRUG PRICING

Offered by M .

Add at the end of subtitle E the following:

SEC. 30523. GAO REPORT.

2 Not later than June 1, 2025, the Comptroller General 3 of the United States shall submit a report to Congress on the impact of the previous sections of this part (including amendments made by such sections) on research and 5 development spending by manufacturers of applicable 6 drugs, including— 7 8 (1) expected or actual increases or decreases in 9 the number of Food and Drug Administration new 10 and supplemental drug applications and new or sup-11 plemental biologic license applications over the next 5 years, 10 years, and 30 years; 12 13 (2) aggregated trends in innovation and re-14 search and development spending by pharmaceutical 15 manufacturers, and also delineated by companies' 16 respective annual Medicare part D sales; and

2

1	(3) impact on manufacturers, particularly those
2	in early, pre-revenue stages, to raise capital to invest
3	in pharmaceutical research and development directly,
4	or in partnership with others.

